A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 2824
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PD-L1
Long Form : programmed death-ligand 1
No. Year Title Co-occurring Abbreviation
2020 A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses. AGK-BRAF, ALK, EML4-ALK, IHC, RTD
2020 A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. CTLA-4
2020 A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapyin Switzerland. NSCLC, QALY
2020 A novel IFNalpha-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma. HDAC, HNSCC, IFN-alpha, lncRNAs
2020 A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations. NSCLC, PFS
2020 Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry. FFPE, IHC, MS
2020 Adjuvant pembrolizumab versus high-dose interferon alpha-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study. AEs, IFN alpha-2b, RFS, TMB
2020 Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. AEs, AKI, CI, ORs
2020 Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. ICB, LUAD, NMF, TIDE, TMB
10  2020 Analysis of PD-L1 Transcriptional Regulation in Ovarian Cancer Cells by Chromatin Immunoprecipitation. ChIP, IFN-gamma, OC
11  2020 Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. BMI, GI, irAEs, LTD, NSCLC, ORs, RCC, WHO
12  2020 Anti-tumor and immunomodulatory activity of the aqueous extract of Sarcodon imbricatus in vitro and in vivo. IL, S. imbricatus
13  2020 Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic. MDSCs, VEGF, VEGFR2
14  2020 ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. ICB
15  2020 Assessing the Impact of Phytochemicals on Immune Checkpoints: Implications for Cancer Immunotherapy. PD-1
16  2020 Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. OS
17  2020 Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. ADC, CI, EGFR, HR, IHC, ORR, PFS, TKI
18  2020 Association between radiotherapy-induced alteration of programmed death ligand1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. OS, PD-1, PD-L1 IC, PD-L1 TC
19  2020 Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. TILD, UTUC
20  2020 Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. HCC, TACE, TIM-3
21  2020 B lymphocytopenia and Bregs in a not-to-die murine sepsis model. CLP, IFN-gamma, IL
22  2020 Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. PD-1
23  2020 Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). IHC, NSCLC
24  2020 Biomarkers that may predict response to immunotherapy in ovarian malignancies. ICB, IHC
25  2020 Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine. DC, NPs, siRNA
26  2020 BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes. BTLA, IHC, NSCLC, PD-1, RFS, TILs
27  2020 Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET. BM, CIT, CT, LAG-3, mAbs, MRI, PET, PET/CT
28  2020 Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection. ---
29  2020 Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review. PD-1
30  2020 Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. Cdk5
31  2020 Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. NSCLC, TPS
32  2020 Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. ALK, CI, EML4, ORR
33  2020 Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma. CRT, ESCC, IDO1
34  2020 Checkpoint inhibitor immunotherapy in kidney cancer. CTLA-4, PD-1
35  2020 Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. RMS, WES
36  2020 Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. CTLA, ICIs, OS, PD, sPD-L1
37  2020 Clinical activity of programmed cell death 1 (PD-1) blockade in never, light,and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. DOR, HR, ICIs, NSCLC, ORRs, PD-1, PFS, TMB, TPS
38  2020 Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. ACB, CGP, GAs, IHC, IO, MSI, SCC, TCs, TILs, TMB, UC
39  2020 Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. NSCLC, TPS
40  2020 Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes. PD-1, TAMs, TLR2
41  2020 Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma. ADC, AUC, CT, F-FDG, IC, TC
42  2020 Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma. EGFR, IHC, NSCLC, TKI
43  2020 Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer. ALK, EGFR, FISH, IHC, NSCLC
44  2020 Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. QALYs
45  2020 Cytology for PD-L1 testing: A systematic review. NSCLC, PD-1
46  2020 Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma. APC, DARA, MM, pDC
47  2020 Dendritic cells treated with a prostaglandin I2 analog, iloprost, promote antigen-specific regulatory T cell differentiation in mice. DC, OVA, PGI2, Treg
48  2020 Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas. HIF-1alpha, NF2, PD-1, PDGFRbeta, TAMs, TME, VEGFR1
49  2020 Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold. PD-1
50  2020 Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. HCC, IFNG, MEF2D, MEF2D, SIRT7
51  2020 Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells. ARE, DOX, TTP
52  2020 Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-kappaB inhibitor for antitumor immunotherapy. aPD-1, CUR, NF-kappaB, TAMs
53  2020 Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-betaRII agent: status of preclinical and clinical advances. TGF-beta, TME
54  2020 Durvalumab induced sarcoid-like pulmonary lymphadenopathy. ICIs, irAEs
55  2020 Effects of Decalcifying Agents of Variable Duration on PD-L1 Immunohistochemistry. FA/MC, IHC
56  2020 Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75years) with non-small cell lung cancer. NSCLC, OS, PD, PFS, PS
57  2020 Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression. HCC, TMB
58  2020 Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. ICIs, SC, TMB
59  2020 Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. BOR, OS, PFS
60  2020 Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. CTLA-4, GM-CSF
61  2020 Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. HDAC3, NSCLC
62  2020 Enhanced Prevention of Breast Tumor Metastasis by Nanoparticle-Delivered Vitamin E in Combination with Interferon-Gamma. alpha-TOS, IFN-gamma, LCCP, NPs
63  2020 Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-gamma to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy. mAb, TILs
64  2020 Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma. BRD4, TSCC
65  2020 Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. IHC
66  2020 Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer. ATRA, GC
67  2020 Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma. ICC
68  2020 Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. ILD, NSCLC, OR
69  2020 Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. CI, FAEs, ORs, RCTs
70  2020 First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis. AnP, ICERs, ITT, QALYs
71  2020 Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma. FOV, ICIs, MCC, PD-1, TCs, TILs
72  2020 Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. ICB
73  2020 Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment. ALCL, ALK, TAMs, TILs
74  2020 GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy. HDAC, MHCA
75  2020 Hepatitis B virus-triggered PTEN/beta-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion. HBp, HBV, HBx, PD-1
76  2020 Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. ADCs, AdSqLCs, mADCs
77  2020 High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. ACRG, CPS, EBV, GC, IHC, MSS
78  2020 High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer. ---
79  2020 IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway. HPV, IFI16
80  2020 Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. NSCLC, OS
81  2020 Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. ECOG, HR, ICIs
82  2020 Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. CD8, dMMR, TIL, TMIT
83  2020 Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. CTLA-4, ICPIs, imAEs, PD-1
84  2020 Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type. cHL, LPDs, MTX
85  2020 Immunosuppression in Cows following Intramammary Infusion of Mycoplasma bovis. blood MNCs, CFD, CTLA-4, FCN1, LAG3, milk MNCs, PD-1, TNFSF13
86  2020 Immunotherapeutic approaches for small-cell lung cancer. ICIs, OS, SCLC
87  2020 Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer. HNSCC, RT
88  2020 Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association with Vascular Formation. HCC, sPD-L1
89  2020 In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides. PD-1
90  2020 Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer. PCa, PD-1, SA, TILs, Tim-3
91  2020 Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma. AC, TAM
92  2020 Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice. PD-1, TB
93  2020 Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer. TNBC
94  2020 Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. BC, HSCC, IC, ICC, OPA, TC, UC
95  2020 Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype. NSCLC
96  2020 Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer invitro and invivo. ---
97  2020 LINC00116 enhances cervical cancer tumorigenesis through miR-106a/c-Jun pathway. RT-qPCR
98  2020 LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a. OS, RT-qPCR
99  2020 Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. HR, NSCLC, OS, TPS
100  2020 Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report. PPC